Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Other
  • S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC
  • Other

S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

OncLive Podcast

In this podcast, experts Narjust Florez, MD, FASCO; David Carbone, MD, PhD; and Edward Garon, MD, MS; discuss the use of KRAS-, NRG1-, MET-, and ROS1-targeting agents to transform patient care in adva

OtherOncologyRead full story

pharminent March 27, 2026 (Last updated: March 30, 2026)

OncLive Podcast

In this podcast, experts Narjust Florez, MD, FASCO; David Carbone, MD, PhD; and Edward Garon, MD, MS; discuss the use of KRAS-, NRG1-, MET-, and ROS1-targeting agents to transform patient care in adva

OtherOncologyRead full story

Post navigation

Previous: Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents
Next: Lilly puts up to $2.75bn into Insilico alliance

Related Stories

  • Other

ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

pharminent June 2, 2026
  • Other

ASCO26: Symptom-tracking app helps advanced cancer patients

pharminent June 2, 2026
  • Other

All eyes on Revolution, bispecific antibodies and more at ASCO26

pharminent May 26, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.